Researching COVID to enhance recovery (RECOVER) autopsy tissue pathology study protocol: Rationale, objectives, and design

4

5 Short Title: RECOVER-Autopsy study protocol

6 Andrea B. Troxel^{1*¶}; Marie-Abele C. Bind^{2¶}; Thomas J. Flotte³; Carlos Cordon-Cardo⁴; Lauren

7 A. Decker⁵; Aloke V. Finn⁶; Robert F. Padera⁷; R. Ross Reichard³; James R. Stone⁸; Natalie L.

8 Adolphi⁹; Faye Victoria C. Casimero⁸; John F. Crary¹⁰; Jamie Elifritz¹¹; Arline Faustin¹²; Saikat

9 Kumar B. Ghosh¹³; Amanda Krausert⁴; Maria Martinez-Lage⁸; Jonathan Melamed¹⁴; Roger A.

10 Mitchell, Jr.¹⁵; Barbara A. Sampson⁴; Alan C. Seifert¹⁶; Aylin Simsir¹²; Cheryle Adams¹⁵;

11 Stephanie Haasnoot¹⁰; Stephanie Hafner³;; Michelle A. Siciliano⁷; Brittany B. Vallejos¹⁷; Phoebe

12 Del Boccio¹; Michelle F. Lamendola-Essel¹⁸; Chloe E. Young¹⁸; Deepshikha Kewlani¹⁸;

13 Precious A. Akinbo¹; Brendan Parent¹; Alicia Chung¹; Teresa C. Cato¹; Praveen C. Mudumbi¹;

14 Shari Esquenazi-Karonika¹; Marion J. Wood¹; James Chan²; Jonathan Monteiro²; Daniel J.

15 Shinnick²; Tanayott Thaweethai²; Amber N. Nguyen²; Megan L. Fitzgerald¹⁹; Alice A.

16 Perlowski²⁰; Lauren E. Stiles²¹; Moira L. Paskett¹⁴; Stuart D. Katz^{18&}; Andrea S. Foulkes^{2&} on

17 behalf of the RECOVER Initiative^

18

¹ Department of Population Health, New York University Grossman School of Medicine, New
York, NY, USA.

² Department of Biostatistics, Massachusetts General Hospital, Boston, MA, USA.

³ Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN,

23 USA.

- ⁴ Department of Pathology, Molecular and Cell-Based Medicine, Mount Sinai Health System,
- 25 New York, NY, USA.
- ⁵ Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque,
- 27 NM, USA.
- ⁶ Department of Pathology, CVPath Institute, Gaithersburg, MD, USA.
- ⁷ Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
- ⁸ Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
- ⁹ Office of the Medical Investigator, University of New Mexico School of Medicine,
- 32 Albuquerque, NM, USA.
- ¹⁰ Department of Pathology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY,
- 34 USA.
- 35 ¹¹ Departments of Radiology and Pathology, University of New Mexico, Albequerque, NM,
- 36 USA.
- 37 ¹² Department of Pathology, New York University Grossman School of Medicine, New York,
- 38 NY, USA.
- ¹³ Department of Molecular Biology and Genomics, CVPath Institute, Gaithersburg, MD, USA.
- 40 ¹⁴ Department of Anatomical Pathology, NYU Langone Hospital Long Island, Mineola, NY,
- 41 USA.
- 42 ¹⁵ Department of Pathology, Howard University College of Medicine, Washington DC, USA.
- 43 ¹⁶ Biomedical Engineering and Imaging Institute, Department of Radiology, Graduate School of
- 44 Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- 45 ¹⁷ Office of the Medical Investigators, Department of Research, University of New Mexico,
- 46 Albuquerque, NM, USA.

- 47 ¹⁸ Department of Medicine, New York University Grossman School of Medicine, New York,
- 48 NY, USA.
- 49 ¹⁹ Patient-Led Research Collaborative on COVID-19, Washington DC, USA.
- ²⁰ Blooming Magnolia, Los Angeles, CA, USA.
- 51 ²¹ Department of Neurology, Stony Brook University Renaissance School of Medicine, Stony
- 52 Brook, NY, USA.
- 53 *Corresponding Author
- 54 Andrea.Troxel@nyulangone.org
- 55 These authors contributed equally to this work and are co-lead authors.
- ⁶ [&]These authors also contributed equally to this work and are co-senior authors.
- 57 Authorship has been determined in accord with ICMJE recommendations
- 58 ^Membership of the RECOVER Initiative is provided in the Acknowledgements

59 Funding

- 60 This research was funded by the National Institutes of Health (NIH) Agreement OTA
- 61 OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER)
- 62 research Initiative.

63 **Competing interests**

- 64 Brendan Parent reports receiving a research gift from United Therapeutics. The remaining co-
- authors have no competing interest to declare.

66 List of Institutions

67 Funding Source: NIH 10T2HL161847-01

68

69 Abstract

70 **Importance:** SARS-CoV-2 infection can result in ongoing, relapsing, or new symptoms or organ 71 dysfunction after the acute phase of infection, termed Post-Acute Sequelae of SARS-CoV-2 72 (PASC), or long COVID. The characteristics, prevalence, trajectory and mechanisms of PASC 73 are poorly understood. The objectives of the Researching COVID to Enhance Recovery 74 (RECOVER) Tissue Pathology Study (RECOVER-Pathology) are to: (1) characterize prevalence 75 and types of organ injury/disease and pathology occurring with PASC; (2) characterize the 76 association of pathologic findings with clinical and other characteristics; (3) define the 77 pathophysiology and mechanisms of PASC, and possible mediation via viral persistence; and (4) 78 establish a post-mortem tissue biobank and post-mortem brain imaging biorepository. 79 Methods: RECOVER-Pathology is a cross-sectional study of decedents dying at least 15 days 80 following initial SARS-CoV-2 infection. Eligible decedents must meet WHO criteria for 81 suspected, probable, or confirmed infection and must be aged 18 years or more at the time of 82 death. Enrollment occurs at 7 sites in four U.S. states and Washington, DC. Comprehensive 83 autopsies are conducted according to a standardized protocol within 24 hours of death; tissue 84 samples are sent to the PASC Biorepository for later analyses. Data on clinical history are 85 collected from the medical records and/or next of kin. The primary study outcomes include an 86 array of pathologic features organized by organ system. Casual inference methods will be 87 employed to investigate associations between risk factors and pathologic outcomes. 88 **Discussion:** RECOVER-Pathology is the largest autopsy study addressing PASC among US 89 adults. Results of this study are intended to elucidate mechanisms of organ injury and disease 90 and enhance our understanding of the pathophysiology of PASC.

91 Keywords: SARS-CoV-2; autopsy study; decedents; tissue pathology; COVID-19

92 Clinicaltrials.gov number: NCT05292274

93

94 Introduction

95 Background information

96 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus
97 strain that emerged at the end of 2019. This strain primarily spreads through aerosols in
98 expiratory gasses in infected individuals with and without symptoms, resulting in the highly
99 contagious coronavirus disease 2019 (COVID-19) and a global pandemic. As of December 2022,
100 approximately 653 million people were infected with COVID-19, with at least 6.7 million deaths
101 globally ¹.

102 Ongoing, relapsing or new symptoms and organ dysfunction after the acute phase of SARS-

103 CoV-2 infection (\geq 30 days) are now termed post-acute sequelae of SARS-CoV-2 infection

104 (PASC), often referred to as Long COVID². The underlying pathophysiology of persistent

symptoms after SARS-CoV-2 infection is unknown but may be attributable to mechanisms such

106 as viral persistence, reactivation of other viruses such as Epstein-Barr virus, vascular endothelial

107 activation and thrombosis, autonomic nerve damage, neuroinflammation in the central nervous

108 system, immune dysregulation including activation of auto-immunity, and/or organ damage

109 caused by hyper-inflammatory response during the acute phase of the disease ^{3,4}. Other

110 contributing causes may include complications of critical illness related to prolonged intubation,

111 prolonged bed rest, and malnutrition, and disruptions of health care access. The role of

112 sociodemographic, clinical, and biological factors is likely to be complex and multifaceted.

113 This study is part of the NIH Researching COVID to Enhance Recovery (RECOVER) Initiative,

114 which seeks to understand, treat, and prevent the post-acute sequelae of SARS-CoV-2 infection

115 (PASC). For more information on RECOVER, visit <u>https://recovercovid.org/</u>. The goals of the

116 RECOVER tissue pathology study (RECOVER-Pathology) are to identify, evaluate, and 117 characterize the clinical manifestations of PASC by comparing decedents with prior SARS-CoV-118 2 infection who died with and without PASC and the risk factors associated with the severity of 119 these clinical manifestations. This cross-sectional study focuses on the pathologic manifestations 120 of SARS-CoV-2 infection, while explicitly considering sex as a biological variable and the 121 impact of racial and ethnic disparities on autopsy findings. Data acquired from this study will 122 provide accurate and quantifiable measures for PASC symptoms in selected populations to allow 123 for comparisons among groups and, together with the adult and pediatric cohort studies, will 124 provide insights into mechanisms related to pathogenesis of PASC and its underlying biology. 125 Autopsies are valuable for elucidating the pathophysiologic mechanisms of novel and poorly 126 understood diseases by enabling deep phenotyping of tissues throughout the body ⁵. Autopsies 127 played a critical role in understanding the pathologic changes in patients dying from acute 128 COVID-19. In this setting, the lungs often showed diffuse alveolar damage and pulmonary 129 thrombi ^{6,7}; extra-pulmonary changes were also identified. Microthrombi and ischemic changes 130 were identified in organs throughout the body ^{6,8-11}. Chronic inflammatory infiltrates and occasionally myocarditis were identified in the heart ^{6,8-11}. Hypoxic-ischemic changes, infarcts, 131 132 and white matter hemorrhagic lesions were identified in the brain; these may be mediated by 133 immune complexes and complement-activating endothelial cells and platelets ^{12,13, 14}. Ex vivo 134 magnetic resonance imaging performed on brain tissue of deceased children showed 135 abnormalities such as white matter signal hyperintensity, which corresponded to mineralization 136 ¹⁵. In some patients with acute COVID-19, the peripheral nerves showed neuritis, and the 137 skeletal muscle demonstrated changes such as type 2 atrophy, necrotizing myopathy, and 138 myositis ¹⁶. Similarly, autopsies on patients with PASC helped elucidate the underlying

pathologic changes, specifically whether any of the pathologic features observed during acute
infection persisted after the initial infection in survivors. In addition, autopsies provided some
answers to the clinical challenges of unexpected and sudden clinical decompensation by showing
the macro- and microvascular thrombotic manifestations of the disease and endothelial injury.
Scientific investigation of autopsy tissues bolstered the clinical suspicions of cytokine
interactions with both the innate and adaptive immune system.¹⁷

145 Study rationale

146 PASC is a profound public health crisis, one that may be with us for many years, with symptoms

147 that can be incapacitating, prevent people from working, and increase the risk of mortality in

both adults and children. As of December 2022, there were over 101 million diagnosed cases of

149 COVID-19 in the United States, certainly an underestimate because of undertesting,

underreporting, and home testing, particularly in children ^{18,19}. Given the estimated total number

151 of cases, even a low incidence of PASC would affect millions. The incidence, prevalence,

152 phenotypes, risk factors, mechanisms, and etiology of PASC are currently unknown, limiting

153 opportunities for prevention and treatment ¹⁸. Therefore, autopsy studies are urgently needed.

154 The RECOVER-Pathology study will enhance the knowledge of the effects of SARS-CoV-2

155 infection and define and characterize the clinical spectrum of PASC in decedents. Ultimately, we

- 156 expect these data to elucidate potential mechanisms to inform future preventive and treatment
- 157 studies.

158 Study objectives

159 The overall scientific objectives of this ongoing study are:

160 1. To enhance knowledge of the effects of SARS-CoV-2 infection;

161	2.	To define	and catego	orize the	clinical s	spectrum	of PASC:
-							

- 162 3. To elucidate potential mechanisms to inform future preventive and treatment163 studies.
- 164 The following specific aims are proposed to achieve these objectives.
- 165 Aim 1. Characterize the prevalence and types of organ injury/disease, pathological features, and
- 166 distinct phenotypes in decedents with acute SARS-CoV-2 infection (dying 15-60 days after
- 167 initial infection), and in decedents with prior SARS-CoV-2 infection (dying >60 days after initial
- 168 infection) with and without symptoms of PASC.
- 169 Aim 2. Characterize the association of pathological findings with clinical measures of disease
- 170 severity and associated risk factors in decedents with prior SARS-CoV-2 infection (dying > 60

171 days after initial SARS-CoV-2 infection) with and without PASC.

- *2a.* Characterize the association of COVID-19 disease severity and treatment with pathological
 findings in decedents with prior SARS-CoV-2 infection with and without PASC.
- 174 2b. Determine whether pre-infection and peri-infection risk and resiliency factors (e.g.,
- 175 demographic, biological factors, and preexisting clinical comorbidities) are associated with
- 176 pathological findings in decedents with prior SARS-CoV-2 infection with and without PASC.
- 177 Aim 3. Define the pathophysiology of and mechanisms associated with pathological findings,
- including the direct and indirect causal effects of clinical risk factors (e.g., comorbidities,
- 179 infection severity, hospitalization, intubation, steroids or other treatments) on pathological
- 180 findings (e.g., inflammation, thrombosis, fibrosis, necrosis) via viral persistence (investigated
- 181 systematically via molecular methods), in decedents with and without PASC.

- 182 Aim 4. Contribute biospecimens to the RECOVER Biorepository, including post-mortem tissue
- 183 samples and post-mortem brain imaging, from decedents with prior SARS-CoV-2 infection, with
- and without PASC. The primary goal of the brain imaging is to find and characterize lesions in
- the CNS via image-directed sampling of identified lesions. A secondary goal is to correlate the
- 186 decedent's MRI findings with those observed in pre-mortem neuroimaging.

187 Methods

188 Study design overview

- 189 RECOVER-Pathology is a cross-sectional study of decedents enrolled in the tissue pathology
- 190 cohort at varying stages after infection with SARS-CoV-2 (Figure 1). This study is conducted in
- 191 the United States and decedents are enrolled through interaction with families of the deceased at
- 192 inpatient, outpatient, and community-based settings. Study data including demographics, pre-
- 193 infection laboratory tests and imaging with medical history, vaccination history, acute SARS-
- 194 CoV-2 infection records, overall health and physical function, and PASC symptoms are collected
- 195 from the electronic health record (EHR) or from family reports of patient medical history using a

196 case report form.

197 Fig 1. Recruitment Sources for RECOVER-Pathology

198

199 Setting

200 RECOVER-Pathology enrollment sites are located in four states (Massachusetts, Minnesota,

201 New Mexico, New York), and the District of Columbia and serve both urban and rural areas with202 racial and ethnic diversity.

203 Study participants

- 204 RECOVER-Pathology enrolls decedents after SARS-CoV-2 infection, defined as probable,
- suspected, or confirmed according to the WHO guideline¹⁷, at varying intervals after infection.
- 206 Some tissue pathology sites are linked with a clinical RECOVER site and may perform autopsies
- 207 on RECOVER decedents. Additional decedents from extant cohorts and clinical cohorts at these

- sites and at other RECOVER Initiative tissue pathology cohort sites who are not enrolled in
- 209 RECOVER, but who have relevant clinical data collected, may be identified for enrollment in the
- 210 tissue pathology cohort. All RECOVER-Pathology sites select decedents for protocol autopsies
- 211 according to the inclusion criteria detailed below.

212 Cohort subgroups

213 The RECOVER-Pathology study comprises two distinct subgroups:

214 **Post-acute cohort:**

- Decedents with prior SARS-CoV-2 infection over the age of 18, with and without current
- 216 or prior PASC-like symptoms, including infected individuals with Multisystem
- Inflammatory Syndrome in Adults (MIS-A), who die at least 30 days following initialinfection.

219 Acute cohort:

- SARS-CoV-2 infected decedents who die between 15 and 30 days following initial
 infection.
- If available, relevant retrospective data prior to enrollment are extracted from the electronic
 health record, existing extant and clinical cohort data, and obtained from next of kin. Decedents
 contribute to aims according to their SARS-CoV-2 infection/PASC history and progression.

225 Inclusion criteria

226 Decedents aged 18 years and older at the time of death are eligible for inclusion. Previously

- 227 infected individuals must have suspected, probable, or confirmed SARS-CoV-2 infection as
- defined by WHO criteria within 24 months of enrollment ²⁰. Decedents are eligible regardless of
- biological sex, race/ethnicity, geography, nationality, severity of disease, underlying health

conditions, history of MIS-A or MIS-C (Multisystem Inflammatory Syndrome in Children), or
 history of SARS-CoV-2 vaccination; those with recurrent and/or post-vaccination (breakthrough)
 SARS-CoV-2 infections are eligible.

233 Classification of PASC

234 Decedents who die more than 30 days following initial infection are initially categorized as

having or not having symptoms of PASC according to the WHO definition ²⁰, published by the

236 World Health Organization (WHO) on October 6, 2021. They defined PASC as a condition

237 occurring "in individuals with a history of probable or confirmed SARS-CoV-2 infection,

usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and

cannot be explained by an alternative diagnosis. Common symptoms include fatigue, shortness

of breath, cognitive dysfunction, and others and generally have an impact on everyday

functioning. Symptoms may be new onset following initial recovery from an acute COVID-19

episode or may persist from the initial illness. Symptoms may also fluctuate or relapse over time.

243 Exclusion criteria

Decedents under the age of 18 at the time of death are not eligible. Decedents dying within 14
days of their initial SARS-CoV-2 infection are not eligible. Decedents in whom the postmortem
interval (PMI) is greater than 24 hours are not eligible. Decedents with any indications of
criminal investigation at time of death are not eligible, nor are those decedents with signs of
decomposition and trauma.

249 Enrollment targets

250 To enhance generalizability of findings, a diverse population of decedents will be enrolled.

Enrollment is stratified by age group, sex, and race/ethnicity to promote sufficient inclusion of

252	non-Hispanic Blacks, Hispanic/Latinx, Asian Americans, Native Hawaiians, and Pacific
253	Islanders with approximately equal distribution between male and female populations.
254	Stratified recruitment
255	Recruitment will occur across sites (described in section 3.2). Recruitment of SARS-CoV-2
256	infected decedents will be targeted at:
257	• 50% female decedents,
258	• 53% non-Hispanic White, 16% non-Hispanic Black, 27% Hispanic/Latinx, and 4% Asian
259	Americans, Native Hawaiians, Pacific Islanders, American Indians, and Native Alaskan
260	decedents,
261	• 57% post-acute decedents with PASC, 29% post-acute decedents without PASC, and
262	14% acute decedents.
263	Note that the autopsy sites will frequently communicate with RECOVER Clinical Sciences Core
264	(CSC) and Data Resource Core (DRC) to maintain adherence with recruitment targets, and to
265	promote balance in decedents with and without PASC with respect to characteristics (e.g., age,
266	sex, race / ethnicity).

267 Study procedures

268 Study organizational structure and study management

269 Scientific leadership for the study and oversight of participating sites is provided by the

270 RECOVER Clinical Science Core (CSC) at the NYU Grossman School of Medicine. The

- 271 RECOVER CSC collaborates with the RECOVER Data Resource Core at Massachusetts
- 272 General Hospital for data management and data storage, and the RECOVER Biorepository at
- 273 Mayo Clinic for biospecimen storage. The activities of the RECOVER cohort studies are
- 274 overseen by a Steering Committee, an Executive Committee, a RECOVER Senior Oversight

- 275 Committee, and an Observational Study Monitoring Board (OSMB) that monitors the study data
- and makes recommendations to correct any problems with the study that may arise. The
- 277 membership composition for each of these committees can be viewed at
- 278 <u>https://recovercovid.org/leadership</u>.

279 Site selection

280 RECOVER-Pathology sites were selected by the National Institutes of Health following a

281 competitive application process in May 2021; these sites were invited to participate in Phase I

activities in summer 2021. The group worked together to collaboratively develop the draft study

283 protocols, outline the modified gross autopsy procedure, identify primary endpoints, and specify

tissues to be sampled. Phase I sites were approved as Phase II enrolling sites by winter 2021.

285 Ethical standards and oversight

All procedures conducted as part of this protocol follow the principles outlined in the report of The Committee for the Oversight of Research Involving the Dead.¹⁸ These include, but are not limited to, dignity, requirement for reasonable scientific validity, confidentiality, consent, noninterference with organ procurement for donation, and protection from harm.

290 The investigators will ensure that this study is conducted in full conformity with guidance taken

from the Code of Federal Regulations (45 CFR 46.102(f)), which states that "research involving

292 deceased persons is not considered human subjects research and does not require IRB oversight,

unless the research involves both living and deceased individuals"²¹.

294 Enrollment

- 295 To facilitate the difficult conversation with decedents' legal next of kin concerning participation
- in RECOVER-Pathology, the CSC developed an information sheet and consent form that
- describes the study in plain language. Study personnel meet with families to discuss the research
- and answer any questions, stressing that participation in the study does not prohibit normal
- 299 funeral and burial practices. Families interested in learning whether a loved one may qualify for
- 300 the study can evaluate enrollment eligibility at <u>https://recovercovid.org</u>.
- 301 The RECOVER-Pathology study also recognizes the importance of engagement with
- 302 communities and families who may be under-represented in research by partnering with other
- 303 federal programs such as the Community Engagement Alliance (CEAL), and the Community
- 304 Engagement Alliance Consultative Resource (CEACR) to extend outreach to a wide variety of

305 potential participants.

306 Study follow-up

307 Upon request, the decedent's next of kin can receive the standard clinical autopsy report with a
308 final anatomic diagnosis (FAD). This report will normally be available to next of kin within 60
309 working days. Next of kin do not receive any research results from the RECOVER-Pathology
310 study. However, aggregated study results will be made available.

311 **Data sources and measurement**

312

Table 1. RECOVER-Pathology Data

Operational Data Types	Structured or Unstructured	Examples
Electronic Health Record (EHR) Data	Unstructured	
EHR data	Structured, complex	

Claims data	Structured, complex	
Biorepository inventory data	Structured, complex	Biospecimens Slides
Biorepository asset data	Structured, complex	
Advanced imaging data	Unstructured	Computer Tomography (CT), Magnetic resonance Imaging (MRI)
Vaccination status data	Structured	
Physical examination and gross findings	Structured, complex	
Whole slide imaging data	Unstructured	Section cut, stained with H&E and scanned (40X resolution)
Autopsy visceral sites digital droplet polymerase chain reaction (ddPCR) for SARS-CoV-2 virus	Structured, complex	
Immunoassays and 'omics data	Structured, complex	Genomics, Proteomics, Transcriptomics, Metabolomics, Meta- genomics microbiome, Epigenetics

313

314 Data may be obtained from multiple sources: directly from the decedent's next of kin, from

315 existing research records (if participating in an ongoing research study, e.g., RECOVER, extant

316 cohorts, clinical cohorts), from the decedent's electronic health record or existing registries, or

317 from insurance claims data.

318 Pre-existing EHR data will be extracted electronically where possible or abstracted and recorded

319 on structured electronic case report forms (eCRFs). Prior to data use, a Health Insurance

320 Portability and Accountability Act of 1996 (HIPAA) authorization is obtained from next of kin,

321 subject to the special provisions that apply post-mortem, which allow for special disclosure

322 provisions that are relevant to deceased individuals ²¹. De-identified data collected from any

323 source are recorded in the RECOVER-Pathology study database, with electronic Case Report324 Forms (eCRFs).

325 Study size

- 326 The RECOVER-Pathology study aims to enroll 700 decedents, including 100 with acute SARS-
- 327 CoV-2 infection dying 15-60 days after infection, and 600 with prior SARS-CoV-2 infection
- 328 (dying >60 days after infection); of these 600, we anticipate 400 with PASC and 200 without
- 329 PASC. These numbers provide adequate power to evaluate the multiple hypotheses associated
- 330 with our aims (**Table 2**).

Table 2. Sample size for the RECOVER Tissue Pathology Study by PASC status

	PASC	Total	
	Without PASC	With PASC	
Post-acute decedents (dying > 60 days after SARS-CoV-2 infection)	200	400	600
Acute decedents (dying 15-60 days from SARS-CoV-2 infection)	100		100
Total	300	400	700

331 Statistical methods

332 **Power considerations**

333 To address Aim 1, row 6 in Table 3 provides detectable effect sizes and detectable differences in

334 proportions between PASC+ and PASC- decedents for quantitative and dichotomous

335 pathological features. Results are given without and with a multiple comparison adjustment

336 (assuming 50 tests, alpha=0.001 conservative control).

337

Table 3. Detectable effect measures

Total sample size (not including acute decedents)	otal ample ize (not ncluding cute ecedents)Number of post- acute decedent s with PASCNumber of post-acute decedents without PASCDetectable standardized effect 		Detectable difference in proportion between groups of post-acute decedents with and without PASC with 80% power, alpha=0.05, 0.001 (i.e., without and with multiple comparison adjustment), based on two independent groups, two-sided comparison of proportions		
			multiple comparison adjustment), based on two independent group, two-sided comparison of means	Proportion with feature = 0.2 in PASC- individuals	Proportion with feature = 0.4 in PASC- individuals
300	150	150	0.32, 0.48	0.14, 0.22	0.16, 0.24
300	200	100	0.34, 0.51	0.15, 0.24	0.17, 0.25
400	200	200	0.28, 0.42	0.13, 0.19	0.14, 0.21
400	267	133	0.30, 0.44	0.13, 0.20	0.15, 0.22
600	300	300	0.23, 0.34	0.10, 0.15	0.12, 0.17
600	400	200	0.24, 0.36	0.11, 0.16	0.12, 0.18

г

To address Aim 2, a sample size of 400 within one group (e.g., post-acute decedents with PASC) will have greater than 80% power to detect a small effect size, i.e., Cohen's d=0.28 between individuals with and without the risk factor, assuming 50% of individuals have the risk factor (i.e., 200 with and 200 without the risk factor; row 3 in Table 3).

To address Aim 3 and characterize the detectable effect sizes from the subset of decedents who undergo brain imaging, for example, please see the first row of Table 3. A sample size of 300 provides 80% power to detect a moderate effect size of d=0.32 between individuals with and without the risk factor (within the specified group), assuming 50% of individuals have the risk factor. These calculations are based on a two-group, two-sided comparison of means, and controlling type 1 error at 0.05.

349

350 Methods of data collection

The majority of the study data are collected at autopsy according to the standardized autopsy protocol described in the appendix** These data include structured fields for the gross autopsy findings. The microscopic findings are captured as text fields, and will later be coded into approved terms using SNOMED (Systematized Nomenclature of Medicine) codes; these clinical terminology codes will be finalized following review by the responsible pathologist. Similarly, the FAD will be coded using a standard set of approved terms. Additional EHR and other research data are extracted and entered into eCRFs.

358 Biospecimen collection is handled in two ways, depending on stability of the sample:

Samples for analytes that require rapid freezing are processed locally and sent to the
 central RECOVER biorepository on dry ice;

- 361 2) Other samples are fixed in formalin and shipped directly to the centralized RECOVER
- 362 biorepository for processing.

363 **Primary endpoints**

- 364 Our statistical analyses will examine a number of primary pathological outcomes including, but
- 365 not limited to, those described in Table 4.

 Cardiovascular system fibrosis non-ischemic inflammation acute ischemic injury infarct atherosclerosis /	 fibrosis inflammation thrombosis presence of SARS-	 Liver fibrosis inflammation thrombosis presence of SARS-
arteriosclerosis thrombosis presence of SARS-CoV-2	CoV-2	CoV-2
 Brain inflammation infarct thrombosis hemorrhages (non-traumatic) atherosclerosis / arteriosclerosis vasculitis vascular malformation / aneurysm neurodegenerative disease presence of SARS-CoV-2 	 Lymph node / spleen Hemophagocytosis reactive lymph nodes presence of SARS- CoV-2 	 Kidney fibrosis inflammation thrombosis presence of SARS- CoV-2

368 Causal inference methods

We will assess the overlap and balance in covariate distributions (e.g., sex, age, race/ethnicity, hospitalization status) between comparative groups (i.e., acute decedents vs. post-acute decedents without PASC, and post-acute decedents with vs. without PASC) using the empirical distributions of the estimated propensity scores ^{22, 23, 24}. If there is evidence of covariate imbalance, we will use matched-sampling techniques to improve balance ^{25, 22}.

374 We will test sharp null hypotheses and report unadjusted and adjusted for multiple comparison ²⁶ Fisher p-values based on the assumed, hypothetical exposure assignment mechanism implied by 375 376 the data and the matched-sampling strategy ^{24, 27} Following the advice of Wasserstein et al. ²⁸, we 377 will "not base our conclusions solely on whether an association or effect was found to be 'statistically significant' (i.e., the p-value passed some arbitrary threshold such as p < 0.05)", but 378 rather also explore Fisherian intervals ²³ and consider model-based inference (e.g., Nevmanian / 379 Frequentist, Bayesian), i.e., we will define an estimand of interest and provide a point estimate and 380 381 a corresponding two-sided uncertainty interval (e.g., 95% confidence interval - CI) for that 382 estimand.

383 Autopsy protocol

Development of the autopsy protocol was based upon the standard ("hospital") autopsy practice in which all the major organs are grossly and microscopically evaluated, additional tissue sampling and specimen collection for ancillary testing is performed routinely, and special research protocols are common. Autopsy pathologists with expertise in COVID and PASC worked, along with patient and caregiver representatives, to develop a broad sampling protocol that could address current and future questions about PASC. To ensure specimen integrity across autopsy sites, the postmortem interval (PMI) between death and autopsy is established at

391 24 hours or less, which includes transportation of the decedent and other elements (e.g., family392 time with decedent, consenting for autopsy).

393 A systematic documentation process for the accurate tracking and transfer of specimens to the

394 biobank is critical and was developed collaboratively by the consortium. Upon completion of the

autopsy, the samples are logged into a database for tracking and shipping to the PASC

396 Biorepository Core (PBC). Once the autopsy report is finalized, the relevant clinical information

397 and diagnostic findings are entered into a structured database. The database was developed with

input and subject matter expertise by the cohort pathologists, working in tandem with the CSC

and DRC.

400 **Biorepository**

401 The centralized PBC was established at the Mayo Clinic to standardize the collection of samples

402 from RECOVER-Pathology, as well as to catalog, store and distribute samples. The PBC

403 provides training in sample collection, a manual of procedures, and kits for supplies with sample

404 return mailing containers. The biospecimen collection process is summarized in Table 5.

405

406

Table 5: Biospecimen collections

Collection Container	# of Container(s)	Collection tube Volume (mL)	Fraction	Aliquot Volume
Blood Spot Card	1	N/A	Whole Blood	One card with 4 blood spots
Serum Separator Tube (SST)	2	8.5	Serum	10 x 1 mL
Cerebrospinal Fluid (CSF)	10	N/A	CSF	10 x 1 mL
Bronchial Swab	1	N/A	Cells	Entire tube
Stool	1	25	Stool	25 mL
56 Tissues (In duplicate)	112	Cryosette™	Snap Frozen Tissue	17 mm diameter, not to exceed 4 mm in thickness x 2
56 Tissues	56	Standard Tissue Cassette	FFPE Tissue	2 x 2 x 0.4 cm

407 The PBC tissue specimen list for each tissue site sampled in the RECOVER-Pathology protocol

408 is outlined in Table 6.

409

410

Table 6: PBC Tissue Specimen Table

Block #	Tissue Description	Block #	Tissue Description
01	Sural nerve	27	Lung, lesional tissue
02	Peroneal nerve	28	Spleen
03	Skin, calf including subcutis	29	Bone marrow (rib squeeze)
04	Muscle, gastrocnemius	30	Pancreas
05	Muscle, psoas	31	Liver, right lobe (central)
06	Duodenum	32	Mesenteric fat
07	lleum	33	Kidney, right or left
08	Colon, right	34	Renal lesional
09	Colon, descending/sigmoid	35	Testis
10	Adrenal	36	Ovary
11	Aorta, ascending	37	Fallopian tube
12	Right ventricle, Posterior	38	Olfactory bulb
13	Left ventricle, lateral	39	Frontal cortex with leptomeninges
14	Left ventricle, basal	40	Basal ganglia
15	Right atrium/SVC (near SA node)	41	Thalamus
16	Left atrium	42	Hippocampus
17	Coronary artery, right	43	Occipital cortex
18	Coronary artery, left	44	Amygdala
19	Cardiac lesional tissue	45	Pons

20	Hilar/mediastinal lymph nodes	46	Choroid plexus
21	Trachea	47	Medulla (area postrema)
22	Right upper lobe, with pleura	48	Cerebellum with dentate
23	Right middle lobe	49	Dura with sinus
24	Right lower lobe	50	Spinal cord (thorax)
25	Left upper lobe, with pleura	51	Sympathetic chain with ganglia
26	Left lower lobe	56	Dorsal root ganglia

411 Tissue samples are collected in triplicate, one sample for formalin-fixed, paraffin embedding

412 (FFPE) and two snap-frozen samples. Tissue is collected from fifty-two specified sites (see

413 Figure 2 and Table 6). The autopsy prosectors have the option of selecting four additional tissue

414 sites to document findings at autopsy that are not included in the specified sample sites.

415 Fig 2: Specified Tissue Collection Sites

416

The collection sites process the tissue into FFPE and snap-frozen blocks at their site and send these blocks to the PBC. At the PBC, the blocks are sectioned, stained for hematoxylin and eosin, and the whole slide is imaged at 40x. The slides are reviewed to confirm that they are from the specified sites. The images are transferred to an image repository. The slides and blocks are stored at the PBC.

422 Role of the Study Coordinator

423 In the RECOVER workstream, site coordinators play an important role in screening, consenting,

424 data entry, and assisting the pathology team by conducting specimen procurement procedures.

425 Hundreds of decedents may be screened daily to find qualified candidates. Workflows and alerts 426 developed by the coordinators streamline and facilitate the screening process. Candidates are 427 identified and eligibility is assessed through review of the decedent's medical history in Epic, 428 other electronic health records (EHRs), or via other available medical records, and coordinators 429 routinely query EHRs for clinical notes and reach out to next of kin to collect as much clinical 430 data as possible. When decedents are deemed eligible for the study, the site coordinator assists 431 the attending clinician with contacting the legal next of kin to obtain consent. The CSC works 432 with site coordinators to facilitate timely and accurate data collection. To ensure that ethical and 433 legal requirements are met, staff are trained on communication and recruitment language 434 strategies. Recruitment materials designed with the goal of informing and comforting the 435 families are provided during the consenting process. Once consent is given, site coordinators arrange transfer of the decedent to the autopsy suite. Each coordinator strives to ensure that the 436 437 transport process allows the family time with their deceased loved one, while maintaining control 438 of the timeline to ensure compliance with the 24-hour PMI requirement. If any urgent issues 439 occur, staff are prepared to offer support to help address the issue and facilitate enrollment of 440 decedents. The CSC also assists by routine monitoring of enrolling sites, to ensure that sites 441 maintain target goals, good documentation, and operational procedures.

442 **Discussion**

In contrast to most autopsies, the RECOVER-Pathology protocol comprehensively samples
tissues with and without any gross or microscopically identifiable pathology. The extensive
specimen collection and snap freezing require a team approach, and the efficiency is driven by
each team member's knowledge of the protocol and associated specimen processing. The

protocol has been implemented across a range of autopsy practices and will provide a richresource for future research.

Another distinct feature of this protocol is that the autopsy pathologists routinely seek
information regarding SARS-CoV-2 infection from multiple outside sources on all cases. Both
medical examiners and hospital-based autopsy pathologists will then seek permission for the
study and the autopsy from the decedent's next of kin. This exemplifies a new and expanding
role for autopsy pathologists as monitors of infectious disease throughout the entire population of
the recently deceased.

455 Pathological changes, including persistence of virus within tissues, have been identified in autopsies of patients dying from acute SARS-CoV-2 infection, as well as in patients who have 456 457 recovered from COVID-19. Persistent viral shedding of SARS-CoV-2 was detected by PCR in 458 the stool up to 210 days after the onset of disease ³⁰, in small bowel biopsies up to 173 days from the onset of disease ³¹, in gastrointestinal biopsy specimens 7 months after the onset of disease 459 460 and associated with gastrointestinal symptoms and symptoms of PASC ³². Virus has also been 461 detected by PCR in the cerebrospinal fluid of a patient 114 days after the onset of disease ³³, and 462 in lung tissue up to 108 days after the onset of disease ³⁴. SARS-CoV-2 was found during 463 autopsy in heart tissue by in-situ hybridization and RNA profiling up to 48 days from the onset 464 of disease ³⁵. These studies raise the question of whether viral persistence may be an underlying 465 cause of PASC. Previous single-cell RNA profiling from infected lung tissue from autopsies 466 demonstrated that the virus is able to enter diverse cell types ²⁶. The RECOVER-Pathology protocol will enable the determination of whether a reservoir of proliferating virus exists in 467 468 patients with PASC and which tissues and cell types are involved. While a definitive timeline for 469 development of PASC remains elusive, the definition of PASC will be refined in real time by

data obtained from all of the RECOVER cohort studies; the RECOVER-Pathology protocol will
be amended to reflect these changes. RECOVER-Pathology will make important contributions to
our understanding of the mechanisms of PASC, and may lead to additional discoveries and
therapeutic interventions.

474 **Disclaimer statement**

475 This content is solely the responsibility of the authors and does not necessarily represent the

476 official views of the RECOVER Program, the NIH or other funders. This research was funded by

- 477 the National Institutes of Health (NIH) Agreement OTA OT2HL161847 (contract number 646-
- 478 501-3654) as part of the Researching COVID to Enhance Recovery (RECOVER) research

479 program.

480 Acknowledgements

481 We would like to thank the National Community Engagement Group (NCEG), all patient,

482 caregiver and community representatives, and the families who gave permission for their loved

483 ones to participate in this autopsy study; we honor the contributions of all participants enrolled in

484 the RECOVER Initiative.

485 **Supporting information**

486 The supporting information is provided in a supplemental appendix file.

References

- Worldometer. (2022). Coronavirus Cases. Retrieved 03 Aug 2022, from https://www.worldometers.info/coronavirus/
- Callard F, Perego E. How and why patients made Long Covid. Soc Sci Med. 2021 Jan;268:113426. doi: 10.1016/j.socscimed.2020.113426. Epub 2020 Oct 7. PMID: 33199035; PMCID: PMC7539940.
- Baker SR, Halliday G, Ząbczyk M, Alkarithi G, Macrae FL, Undas A, Hunt BJ, Ariëns RAS. Plasma from patients with pulmonary embolism show aggregates that reduce after anticoagulation. Commun Med (Lond). 2023 Jan 28;3(1):12. doi: 10.1038/s43856-023-00242-8. PMID: 36709220; PMCID: PMC9883810.
- Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nature Medicine* 2021; 27(4): 601-15.
- Basso C, Stone JR. Autopsy in the Era of Advanced Cardiovascular Imaging. *European Heart Journal* 2022; 43(26): 2461-8.
- Bryce C, Grimes Z, Pujadas E, et al. Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. *Modern Pathology* 2021; 34(8): 1456-67.
- Jackson NR, Zeigler K, Torrez M, et al. New Mexico's COVID-19 experience. *American Journal of Forensic Medicine and Pathology* 2021; 42(1): 1-8.
- Basso C, Leone O, Rizzo S, et al. Pathological features of COVID-19-associated myocardial injury: A multicentre cardiovascular pathology study. *European Heart Journal* 2020; 41(39): 3827-35.

- Rapkiewicz AV, Mai X, Carsons SE, et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. *EClinicalMedicine* 2020; 24:100434.
- Pellegrini D, Kawakami R, Guagliumi G, et al. Microthrombi as a major cause of cardiac injury in COVID-19: A pathologic study. *Circulation* 2021; 143(10):1031-42.
- Bearse M, Hung YP, Krauson AJ, et al. Factors associated with myocardial SARS-CoV-2 infection, myocarditis, and cardiac inflammation in patients with COVID-19. *Modern Pathology* 2021; **34**(7): 1345-57.
- Lee MH, Perl DP, Steiner J, Pasternack N, Li W, Maric D, Safavi F, Horkayne-Szakaly I, Jones R, Stram MN, Moncur JT, Hefti M, Folkerth RD, Nath A. Neurovascular injury with complement activation and inflammation in COVID-19. Brain. 2022 Jul 29;145(7):2555-2568. doi: 10.1093/brain/awac151. PMID: 35788639; PMCID: PMC9278212.
- Solomon IH, Normandin E, Bhattacharyya S, et al. Neuropathological features of Covid-19. *New England Journal of Medicine* 2020; **383**(10): 989992.
- Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y, Lucchinetti CF. Neuropathology of COVID-19: A spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. *Acta Neuropathologica* 2020; 140(1): 1-6.
- 15. Stram MN, Seifert AC, Cortes E, et al. Neuropathology of pediatric SARS-CoV-2 infection in the forensic setting: Novel application of ex vivo imaging in analysis of brain microvasculature. *Frontiers in Neurology*. 2022; 13: 894565.

- Suh J, Mukerji SS, Collens SI, Padera RF Jr, Pinkus GS, Amato AA, Solomon IH.
 Skeletal muscle and peripheral nerve histopathology in COVID-19. *Neurology* 2021;
 97(8): e849-58.
- Maiese A, Manetti AC, La Russa R, et al. Autopsy findings in COVID-19-related deaths: a literature review. *Forensic Sci Med Pathol* 2021; 17(2): 279-96.
- Stokes EK ZL, Anderson KN, et al. Coronavirus Disease 2019 Case Surveillance United States, CDC, January 22–May 30, 2020.
- CDC. United States COVID-19 Cases, Deaths, and Laboratory Testing (NAATs) by State, Territory, and Jurisdiction. August 3, 2022. https://covid.cdc.gov/covid-datatracker/#cases_casesper100klast7days (accessed August 3rd, 2022).
- World Health Organization. (2021). A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021.
- 21. Health information of deceased individuals: Guidance portal. Health Information of Deceased Individuals | Guidance Portal. (n.d.). Retrieved September 03, 2022, from https://www.hhs.gov/guidance/document/health-information-deceased-individuals
- 22. Stuart, Elizabeth A. "Matching methods for causal inference: A review and a look forward." Statistical science : a review journal of the Institute of Mathematical Statistics, vol. 25,1 (2010).
- Imbens, G, & Rubin, D. Causal Inference for Statistics, Social, and Biomedical Sciences: An Introduction. Cambridge: Cambridge University Press (2015).
- 24. Bind M-AC, Rubin DB. Bridging observational studies and randomized experiments by embedding the former in the latter. Statistical Methods in Medical Research, 28, 7, Pp. 1958-1978 (2019).

- 25. Rosenbaum P and Rubin DB. The central role of the propensity score in observational studies for causal effects, Biometrika, 70, 41–55 (1983)
- 26. Lee, J, Forastiere L, Miratrix L, and Pillai N. More Powerful Multiple Testing in Randomized Experiments with Non-Compliance. arXiv:1605.07242 (2016)
- 27. Branson Z. Randomization tests to assess covariate balance when designing and analyzing matched datasets. Observational studies 7, 1-36 (2021)
- Wasserstein R, Schirm A, Lazar N. Moving to a World Beyond "p < 0.05". The American Statistician, 73, 1-19 (2019)
- 29. DeVita MA, Wicclair M, Swanson D, Valenta C, Schold C. Research involving the newly dead: an institutional response. *Crit Care Med* 2003; **31**(5 Suppl): S385-90.
- 30. Batra A, Clark JR, Kang AK, et al. Persistent viral RNA shedding of SARS-CoV-2 is associated with delirium incidence and six-month mortality in hospitalized COVID-19 patients. *Geroscience* 2022; 44(3): 1241-54.
- Natarajan A, Zlitni S, Brooks EF, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. *Medicine (New York)* 2022; 3(6): 371-87.
- 32. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV2. *Nature* 2021; **591**(7851): 639-44.
- Zollner A, Koch R, Jukic A, et al. Postacute COVID-19 is Characterized by gut viral antigen persistence in inflammatory bowel diseases. *Gastroenterology* 2022; 163(2): 495-506.

- 34. Viszlayová D, Sojka M, Dobrodenková S, et al. SARS-CoV-2 RNA in the cerebrospinal fluid of a patient with long COVID. *Therapeutic Advances in Infectious Disease* 2021;
 8:20499361211048572.
- 35. Caniego-Casas T, Martínez-García L, Alonso-Riaño M, et al. RNA SARS-CoV-2 persistence in the lung of severe COVID-19 patients: A case series of autopsies. *Frontiers in Microbiology* 2022; 13:824967.
- Delorey TM, Ziegler CGK, Heimberg G, et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. *Nature* 2021; 595(7865):107-13.



Fig 2

		1			
		STUDY PERIOD			
		Enrollment	Autopsy	Data entry	Post- mortem MRI
	TIMEPOINT**	0	1	2	3
	Enrollment				
	Eligibility screen	х			
	Informed consent	х			
	Autopsy		х		
medRxiv pr <mark>(which wa</mark>	ep int doi: https://toi.org/10.1101/2023.04, s not certified by poer review) is the aut It is made avail	27.23289234; this version for/funder, who has grante ble under a CC-BY 4.0 In	posted May & 2023. The o d medRxiv a license to dis ernational license .	opyright holder for this prepri play the preprint in perpetuity	nt X
	Post-mortem MRI				х

Figure. SPIRIT schedule for the RECOVER-Autopsy Study

Fig 1





sigmoid

Skin, calf including subcutis Gastrocnemius Muscle